Diagnosis using more markers commonly yield a better outcome, so we applied combinations of plasma Fgf21 with other plasma or trait markers for NAFLD, i.e. plasma ALT, plasma CK-18 and body weight. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.